US20080089851A1 - Brown Algae Cell Lyophilisate, Method For The Obtention Thereof - Google Patents
Brown Algae Cell Lyophilisate, Method For The Obtention Thereof Download PDFInfo
- Publication number
- US20080089851A1 US20080089851A1 US11/813,861 US81386105A US2008089851A1 US 20080089851 A1 US20080089851 A1 US 20080089851A1 US 81386105 A US81386105 A US 81386105A US 2008089851 A1 US2008089851 A1 US 2008089851A1
- Authority
- US
- United States
- Prior art keywords
- product
- cells
- keratinocytes
- microsomes
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000199919 Phaeophyceae Species 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 title claims abstract description 15
- 239000002537 cosmetic Substances 0.000 claims abstract description 15
- 230000000295 complement effect Effects 0.000 claims abstract description 9
- 230000008569 process Effects 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims description 14
- SJWWTRQNNRNTPU-ABBNZJFMSA-N fucoxanthin Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]1(C(C[C@H](O)C2)(C)C)[C@]2(C)O1 SJWWTRQNNRNTPU-ABBNZJFMSA-N 0.000 claims description 12
- AQLRNQCFQNNMJA-UHFFFAOYSA-N fucoxanthin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC(=CC=CC=C(/C)C=CC=C(/C)C(=O)CC23OC2(C)CC(O)CC3(C)C)C)CO)C(C)(O)C1 AQLRNQCFQNNMJA-UHFFFAOYSA-N 0.000 claims description 12
- 230000035784 germination Effects 0.000 claims description 5
- 238000003306 harvesting Methods 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 230000032677 cell aging Effects 0.000 claims description 4
- 230000000485 pigmenting effect Effects 0.000 claims description 4
- 230000035882 stress Effects 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 10
- 210000002510 keratinocyte Anatomy 0.000 description 77
- 210000001589 microsome Anatomy 0.000 description 64
- 210000004027 cell Anatomy 0.000 description 57
- VGEREEWJJVICBM-UHFFFAOYSA-N phloretin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 description 54
- 238000011282 treatment Methods 0.000 description 40
- 102000004169 proteins and genes Human genes 0.000 description 28
- 108090000623 proteins and genes Proteins 0.000 description 28
- ZWTDXYUDJYDHJR-UHFFFAOYSA-N (E)-1-(2,4-dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-2-propen-1-one Natural products OC1=CC(O)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O ZWTDXYUDJYDHJR-UHFFFAOYSA-N 0.000 description 27
- YQHMWTPYORBCMF-UHFFFAOYSA-N Naringenin chalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-UHFFFAOYSA-N 0.000 description 27
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 26
- 239000008103 glucose Substances 0.000 description 26
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 24
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 24
- 229950006344 nocodazole Drugs 0.000 description 24
- 239000013642 negative control Substances 0.000 description 20
- 210000003491 skin Anatomy 0.000 description 20
- 150000002632 lipids Chemical class 0.000 description 19
- 230000000694 effects Effects 0.000 description 16
- 230000029058 respiratory gaseous exchange Effects 0.000 description 16
- 230000009758 senescence Effects 0.000 description 16
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 14
- 229960001231 choline Drugs 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 239000000049 pigment Substances 0.000 description 14
- 238000003556 assay Methods 0.000 description 13
- 238000011534 incubation Methods 0.000 description 13
- 239000000872 buffer Substances 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 238000000926 separation method Methods 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000013641 positive control Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 235000021466 carotenoid Nutrition 0.000 description 10
- 150000001747 carotenoids Chemical class 0.000 description 10
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 10
- 102000009027 Albumins Human genes 0.000 description 9
- 108010088751 Albumins Proteins 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 8
- 210000002615 epidermis Anatomy 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 230000004962 physiological condition Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000001085 differential centrifugation Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 229930002875 chlorophyll Natural products 0.000 description 5
- 235000019804 chlorophyll Nutrition 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 229960000890 hydrocortisone Drugs 0.000 description 5
- 229920002521 macromolecule Polymers 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 239000013535 sea water Substances 0.000 description 5
- 235000019155 vitamin A Nutrition 0.000 description 5
- 239000011719 vitamin A Substances 0.000 description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 241000199900 Laminariales Species 0.000 description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000002250 absorbent Substances 0.000 description 4
- 230000002745 absorbent Effects 0.000 description 4
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 4
- 235000005473 carotenes Nutrition 0.000 description 4
- 229930002868 chlorophyll a Natural products 0.000 description 4
- 210000004087 cornea Anatomy 0.000 description 4
- 238000010191 image analysis Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000002085 irritant Substances 0.000 description 4
- 231100000021 irritant Toxicity 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000002438 mitochondrial effect Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000036284 oxygen consumption Effects 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229940045997 vitamin a Drugs 0.000 description 4
- 230000002407 ATP formation Effects 0.000 description 3
- 238000009010 Bradford assay Methods 0.000 description 3
- 241000195493 Cryptophyta Species 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000006540 mitochondrial respiration Effects 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 241000199897 Alaria esculenta Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 244000124209 Crocus sativus Species 0.000 description 2
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241001466453 Laminaria Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- 241001261506 Undaria pinnatifida Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- 238000012742 biochemical analysis Methods 0.000 description 2
- 235000012682 canthaxanthin Nutrition 0.000 description 2
- 239000001659 canthaxanthin Substances 0.000 description 2
- 229940008033 canthaxanthin Drugs 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000004098 cellular respiration Effects 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 2
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- DGNIJJSSARBJSH-NLJAFYFLSA-L magnesium (E)-3-[(3R)-16-ethenyl-11-ethyl-3-methoxycarbonyl-12,17,21,26-tetramethyl-4-oxo-7,24-diaza-23,25-diazanidahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1(22),2(6),5(26),7,9,11,13,15(24),16,18,20-undecaen-22-yl]prop-2-enoic acid Chemical compound [Mg++].CCc1c(C)c2cc3nc(cc4[n-]c(c(\C=C\C(O)=O)c4C)c4[C@@H](C(=O)OC)C(=O)c5c(C)c(cc1[n-]2)nc45)c(C)c3C=C DGNIJJSSARBJSH-NLJAFYFLSA-L 0.000 description 2
- 229940049920 malate Drugs 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 230000036564 melanin content Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000000243 photosynthetic effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical group [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- CPUXXZFMOCKIBJ-UHFFFAOYSA-N 2-hydroxybutanedioic acid;2-oxopropanoic acid Chemical compound CC(=O)C(O)=O.OC(=O)C(O)CC(O)=O CPUXXZFMOCKIBJ-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- JYCQQPHGFMYQCF-UHFFFAOYSA-N 4-tert-Octylphenol monoethoxylate Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 description 1
- 231100000582 ATP assay Toxicity 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 241001291968 Ascoseirales Species 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000024244 Chelis Species 0.000 description 1
- 241000206751 Chrysophyceae Species 0.000 description 1
- 241001262079 Cutleriales Species 0.000 description 1
- LAJXCUNOQSHRJO-ZYGJITOWSA-N Cytochalasin E Chemical compound C([C@H]1[C@@H]2[C@@H]([C@]3(O[C@H]3[C@@H]3/C=C/C[C@H](C)C(=O)[C@](C)(O)/C=C/OC(=O)O[C@@]23C(=O)N1)C)C)C1=CC=CC=C1 LAJXCUNOQSHRJO-ZYGJITOWSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241001442117 Desmarestiales Species 0.000 description 1
- 241000199916 Dictyotales Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000199922 Ectocarpales Species 0.000 description 1
- 241000195522 Fucales Species 0.000 description 1
- 241000195480 Fucus Species 0.000 description 1
- ZWQVYZXPYSYPJD-RYUDHWBXSA-N Glu-Gly-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZWQVYZXPYSYPJD-RYUDHWBXSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000296380 Laminaria hyperborea Species 0.000 description 1
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 1
- 101710200814 Melanotropin alpha Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910004619 Na2MoO4 Inorganic materials 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N O=C=O Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 241000983742 Saccharina Species 0.000 description 1
- 241000983746 Saccharina latissima Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041303 Solar dermatitis Diseases 0.000 description 1
- 241001126801 Sphacelariales Species 0.000 description 1
- 241001264086 Sporochnales Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 241001126807 Syringodermatales Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 241000007142 Tilopteridales Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 241001261505 Undaria Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002225 anti-radical effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000001058 brown pigment Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000001752 chlorophylls and chlorophyllins Substances 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 238000001033 granulometry Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 108010075526 keratohyalin Proteins 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 210000000498 stratum granulosum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9711—Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/04—Preparations for care of the skin for chemically tanning the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
Definitions
- This invention relates to a freeze-dried product of cells of brown algae, the process for obtaining thereof, a cosmetical composition containing them, a food complement containing them and uses thereof.
- the class of brown algae also called Fucophycae or Phaeophyceae, belongs to the Division Chromophyta or “colored algae”, frequently called chrysophyta.
- This Division groups algae the cells of which contain “accessory” carotenoid pigments, such as fucoxanthin, in addition to chlorophyll pigments: chlorophyll a and c.
- the class of brown algae comprises the orders of: Ascoseirales, Chordariales, Cutleriales, Desmarestiales, Dictyosiphonales, Dictyotales, Durvilleales, Ectocarpales, Fucales, Laminariales, Notheiales, Scytosiphonales, Sphacelariales, Sporochnales, Syringodermatales, Tilopteridales.
- All photosynthetic organisms use the pigments to harvest the light energy, usually a form of chlorophyll.
- the standard chlorophyll is the chlorophyll a, and it is essential for the transfer of the captured light energy to the molecules which will make use of this energy.
- Most of the chlorophyll organisms have other pigments to absorb more light but the harvested energy must always be transferred to a molecule of chlorophyll a.
- the brown algae make use of several such “accessory” pigments such as the chlorophyll c and the carotenoids.
- the Phaeophyceae exhibit great amounts of carotenoids in their plastids and these are the brown and yellow pigments which impart them this characteristic brown colour.
- the most important carotenoid pigment of the brown algae is fucoxanthin, the name of which originates from Fucus .
- the fucoxanthin absorbs wavelengths of 500 to 580 nm.
- Carotenoid pigments have an aliphatic or alicyclic structure. They are soluble in fats, what furthers their direct integration into certain membranes. Therefore, their solubility in water can only arise when they are bound to other molecules. This is also the reason that their metabolism is most frequently in direct relation to the metabolism of lipids.
- Carotenoids are also called accessory pigments, since they are bound to transfer the energy harvested by chlorophyll a. These pigments are generally known through the caroten which gave its name to this family of pigments.
- carotenoids particularly for animals and humans, are their food.
- the carotenoids have an antioxydant function in the human plasma, especially for the circulating lipids. This function is expressed also at the cell membrane level where they are incorporated.
- the carotenoids have a direct part in the coloration of the skin (yellow-orange) imitating the natural tan.
- Caroten is used as food complement to be taken a few days before and during the exposition to sunlight in order to accelerate the tan.
- the beta-caroten is the precursor of the vitamin A.
- the intake of beta-caroten delays the outbreak of solar erythema.
- Vitamin A increases the amount of melanin produced under the action of a blue light. Further, the vitamin A has an anti-oxydative protective role.
- the vitamins A and E avoid the oxydative denaturation of the melanin under the action of UV-light.
- caroten is associated to the vitamin C, the vitamin E or to the flavonoids.
- Astaxanthin was shown to be a powerful anti-oxidant.
- the patent application U.S. Pat. No. 6,433,025 describes the oral use thereof for preventing and delaying sunburns.
- Canthaxanthin a further carotenoid pigment, was used as food complement for colouring the skin and for protecting thereof against UV rays (GB 1 323 800). Nevertheless, this use of canthaxanthin is prohibited in France because of the danger of blindness while it is currently marketed in the U.S. (Canthorex, DELTA® Laboratories).
- a freeze-dried product of cells of brown algae in particular of gametophytes, enriched in fucoxanthin, allows to achieve this combination of desired effects: it pigments the epidermis in an entirely harmless way by stimulating the melanogenesis, even without UV irradiation, while protecting it by an anti-radical activity and stimulating its regeneration.
- brown algae have a complex digenetic cycle.
- Laminariales see FIG. 1
- gametophytes are only a set of cells resulting from different mitoses of the spore.
- the gametophyte is transient with time and is only a stage of production of gametes. As it is not developed into a true thalle, it is weakly photosynthetic and contains a maximum amount of protecting pigments: fucoxanthin, compared to the true photosynthesis pigments which are chlorophylls.
- the Applicant has selected this stage of gametophyte in order to obtain a freeze-dried product of cells of brown algae with an extrement enrichment in fucoxanthin, easily and at low cost, compared to a classical extraction of fucoxanthin, from a biomass available in unlimited amounts and throughout the whole year.
- the first subject-matter of the present invention is a freeze-dried product of cells of brown algae enriched in fucoxanthin, in particular comprising at least 1% of fucoxanthin.
- Said cells of brown algae are preferably spores or gametophytes, in a particularly preferred manner, gametophytes.
- the second subject-matter of the present invention is a process for obtaining a freeze-dried product of gametophytes of cells of brown algae comprising the following steps:
- “Mature sporophyte” means a sporophyte comprising spores in special receptacles, for example sores.
- the third subject-matter of the present invention is a cosmetic preparation for topical use comprising a freeze-dried product according to the invention as active ingredient, preferably in an amount ranging from of 0.2 to 5% in weight, more preferably, of 1 to 2% in weight.
- the fourth subject-matter of the present invention is a food complement comprising a freeze-dried product according to the invention as active ingredient.
- the cosmetic preparation according to the invention can be used for pigmenting the skin, for preparing the skin to be exposed to UV rays, for protecting the skin against oxydative stress induced by UV rays and/or for protecting the skin against cellular aging.
- the food complement according to the invention can be used for preparing the skin to be exposed to UV rays.
- FIG. 1 reproduction cycle of Laminariales
- FIG. 2 sections of epidermis treated/untreated stained with HES (hematoxylin/eosine/safran).
- Gametophytes cells were obtained for the following species: Laminaria saccharina, Laminaria hyperborea, Alaria esculenta, Undaria pinnatifida.
- the pieces of thalle were dried on absorbent paper, distributed by 30 on a sheet of absorbent paper and the sheets of absorbent paper were rolled.
- the sheets of rolled absorbent paper containing the pieces of thalli are incubated for 12 h at 15° C. Then they are placed into filtered sea water and afterwards, spores are emitted.
- the spores are incubated in a defined culture medium containing 0.1% of Provasoli solution (see Table 1) in a flask in the presence of light (1800-2000 lux, 24h/24), with slight shaking.
- the temperature is increased by a half degree by day up to 22° C.
- the medium was renewed fortnightly.
- the culture is filtered on a sieve, the cells are rinsed with sea water and freeze-dried in a plate-freeze-drier.
- an ethanol extraction is performed at a rate of 0.05% of freeze-dried product for 10 ml of 70% ethanol, stirring for 6 h in darkness, then filtration.
- a freeze-dried product of gametophytes of the seaweed Undaria pinnatifida (Laminariaciae) is prepared according to Example 2.
- freeze-dried product In order to use this freeze-dried product in a suitable way on skin culture, the freeze-dried product is put back into the culture medium of gametophytes. This mixture is ultrasonicated, then filtered. The result of this filtered product is called ⁇ BB>>.
- Keratinocytes of the TR 146 line spontaneously transformed, amplified, by cell culture in a defined modified MCDB 153 medium were used.
- these human keratinocytes When cultured on the interface air/liquid in a defined medium, these human keratinocytes form a multilayered epithelium without the cornea layer similar to the human cornea.
- the product to be investigated in this case the BB product according to Example 3, is applied at a rate of 30 ⁇ L onto the surface of eight equivalent cultures using a micro-pipette. These cultures are subsequently incubated at 37° C., 5% of CO 2 , for 10 minutes, 1 hour, 3 hours and 24 hours, at a rate of two cultures by incubation period.
- Negative (buffered saline solution) and positive (SDS 0.5% and 1%) controls are prepared sterile and applied in the same way on two cultures, respectively.
- the cellular viability is further measured qualitatively after labelling with a vital dye.
- the MTT system measures the mitochondrial dehydrogenase activity of living cells.
- the key component is the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide or MTT.
- the salt solutions buffered with MTT, in the absence of phenol red, are yellow coloured.
- the mitochondrial deshydrogenases of living cells cut the tetrazolium cycle, thus inducing formation of purple formazan crystals, insoluble in aqueous solutions.
- the crystals formed by the viable cells are trapped in the polycarbonate filters which serve as support to epithelial cultures.
- the cultures turn to a uniform intense blue/purple colour when they are viable, but remain white/yellow in the case of cell mortality.
- Negative control cultures should show an intense blue/purple colour, proof of the viability of mucosa after being in contact for 24 hours.
- Positive control cultures should show a white colour, proof of the cellular mortality as from the 1 st hour of contact.
- the BB product according to Example 3 investigated pure, is not irritant to cells forming the model SKINETHIC® of in vitro reconstructed mucous membrane.
- Keratinocytes of human origin are plated out on polycarbonate filters of 0.63 cm 2 in a defined and supplemented medium (modified MCDB 153 ). The cells are cultured for 10 days on the air/liquid interface, the culture medium being renewed every two days.
- the thus formed epidermis were used for carrying out the study from the 14 th day of culture.
- test was performed in triplicate after incubation for 24 hours of the product, at a rate of 2 ⁇ l by epidermis.
- the control epidermis did not receive any product.
- Epidermis fixed in a 10% formaldehyd solution were embedded into paraffin blocs. Vertical sections of 4 microns were stained with HES (hematoxylin/eosine/safran) and photographs were taken under light microscope.
- HES hematoxylin/eosine/safran
- the cultures should show basal, spineous, granular cell layers and intact orthokeratosic cornea, and the skin stratification should be regular and normal.
- the basal layer cells should be polarized vertically. Numerous keratohyalin grains should be visible (in violet) in the stratum granulosum just under the stratum corneum.
- the BB product according to Example 3 investigated pure, has been shown not to be cytotoxic on reconstructed skins SKINETHI C®.
- the BB product is diluted in ethanol then incorporated into a cosmetic formulation.
- the tested products are:
- the melanin contained in cell lysates was quantified by a spectrophotometrical method. A range of melanin was carried out in parallel with the assay.
- the epidermis skins ware fixed in formaldehyde from the end of incubation, then embedded in paraffin blocs. Subsequently sections of 4 ⁇ m thickness were cut.
- the melanin present in the skin sections was revealed by a specific staining called ⁇ Fontana Masson>>. Said slides by condition were carried out with a magnification ⁇ 400. The visualisable melanin on these slides was quantified by image analysis using the Image J program.
- the formulation “ETOH BB 0.15” increases significantly the melanin content of reconstructed melanized human epidermal skins, not exposed to UVA or to UVB, without re-application (+22% by biochemical analysis, +51% by image analysis).
- the formulation “ETOH BB 0.3” increases significantly the melanin content in reconstructed in reconstructed melanized human epidermal skins, not exposed to UVA or to UVB (+28% by biochemical analysis, +36% by image analysis).
- microsomes of human keratinocytes form a membrane fraction obtained by high-speed differential centrifugation of a cell homogenate. This preparation of microsomes requires the addition of exogenous cofactors such as NADPH.
- the assay was performed in triplicate after the direct treatment of microsomes.
- the obtained microsomes from human keratinocytes in culture were washed 3 times with a PBS buffer without glucose then pre-incubated in 1 ml of the same buffer for 30 minutes at 37° C. Subsequently, this solution was discarded and the microsomes placed into the glucose-free PBS buffer containing 3-0-Methyl glucose (MG) and [ 3 H] 3-0-MG with stirring in a water-bath at 37° C. The capture of 3-0-MG is stopped by addition of 1 ml of cold PBS containing cytochalasine B. The kinetics of incubation was performed between 30 and 120 seconds. The microsomes were further rinsed 2 times with PBS, then dissolved in NaOH (1M) at 4° C., over night. The radioactivity was determined with a scintillation counter.
- the protein assay was performed following the BRADFORD method.
- the increase in absorbance at 595 nm, determined with spectrophotometer, is proportional to the protein concentration.
- microsomes with phloretin strongly inhibits the rate of transport of glucose.
- the treatment of microsomes with the BB product in the 3 concentrations simultaneously with phloretin significantly re-establishes the rate of transport of glucose.
- the kinetics of glucose capture, under inhibiting conditions, is perfectly re-established with the BB product in the 3 used concentrations.
- the assay was performed in triplicate after direct treatment of microsomes.
- the obtained microsomes from human keratinocytes in culture were rinsed 3 times with 25 mM Tris buffer, then preincubated in 1 ml of the same buffer for 30 minutes at 37° C. This solution was then discarded and the microsomes were placed into the 25 mM Tris buffer containing [ 3 H] Choline with stirring in a water bath at 37° C.
- the capture of choline was stopped by addition of a lysis buffer containing (50 mM de Tris, 140 mM NaCl, 1.5 mM MgSO 4 , 0.5% Igepal-Ca-630, 0.2% SDS).
- the kinetics of incubation was performed between 30 and 120 seconds. Subsequently, the microsomes were rinsed 2 times with PBS then dissolved in NaOH (1M) at 4° C. over night. The radioactivity was determined with a scintillation counter.
- the protein assay was carried out following the BRADFORD method.
- the increase in absorbance at 595 nm, determined with a spectrophotometer, is proportional to the protein concentration.
- the obtained results show that the direct treatment of the microsomes with the Diphenhydramin strongly inhibits the rate of transport of lipids.
- the treatment of microsomes with the BB product in the 3 concentrations at the same time as with the Diphenhydramin restores the rate of transport of lipids.
- the kinetics of choline capture, under inhibiting conditions is moderately re-established with the BB product in the used 3 concentrations.
- the assay was performed in triplicate after the direct treatment of microsomes.
- the obtained microsomes from human keratinocytes in culture were rinsed 3 times with a buffer, afterwards pre-incubated in 1 ml of the same buffer for 30 minutes at 3° C. This solution was subsequently discarded and the microsomes were placed into the HBSS buffer containing albumin-FITC with stirring in a water bath at 37° C.
- the capture of albumin is stopped by addition of a Ringer's solution containing 122.5 mM NaCl; 5.4 mM KCl; 1.2 mM CaCl 2 ; 0.8 mM MgCl 2 ; 0.8 Na 2 HPO 4 ; 0.2 NaHPO 4 ; 5.5 mM glucose; 10 mM HEPES, pH 7,4.
- microsomes were treated with Triton X-100 at (0.1% v/v in 3-(N-morpholino) propanesulfonic acid 20 mM, pH 7.4).
- the fluorescence was quantified with a spectrophotometer (excitation 480 nm: emission 520 nm).
- the kinetics of incubation was performed between 30 and 120 seconds.
- the assay of proteins was performed following the BRADFORD method.
- the increase in absorbance at 595 nm is proportional to the concentration of proteins measured with a spectrophotometer.
- the applied method was that of explants allowing to obtain, from a biopsy of human skin, keratinocytes in primary cultures.
- the assays were carried out on keratinocytes between the 2nd and the 4th passage in order to ensure a reproductibility between the different experiences.
- the keratinocytes were divided into multiwell plates (6 wells) at a rate of 10 5 cells per well in 1 ml of culture medium SKINETHIC supplemented with insulin and hydrocortisone. The cells were incubated in the presence and absence of the investigated product.
- the assay was carried out in triplicate on normal human keratinocytes in culture.
- the treatment of keratinocytes with the BB product in the presence and absence of 0.25 mM phloretin was carried out for 20 minutes at 37° C.
- the membrane microsomes were separated by differential centrifugation.
- the assay was carried out in triplicate on normal human keratinocytes in culture.
- the treatment of normal keratinocytes with the BB product in 3 concentrations at the same time as the Diphenhydramin restores the rate of transport of lipids.
- the assay was carried out in triplicate on normal human keratinocytes in culture.
- the senescence is a phenomenon of cellular aging, where the cells are arrested in the phase G 1 of the cell cycle and never enter the synthesis phase leading to the cell division. Senescent cells are characterized by their slow metabolism at synthesis and transport of macromolecules levels.
- the applied method allowed to obtain, from a human skin biopsy, primary cultures of keratinocytes.
- the assays were performed on keratinocytes, between the 8th and the 10th passage, in order to ensure the presence of senescent cells at control cells level.
- the keratinocytes were seeded in multiwell plates (6 wells) at a rate of 10 5 cells per well in 3 ml of culture medium SKINETHIC supplemented with EGF, hydrocortisone, insulin and gentamicyn. Afterwards they are maintained for 5 days in incubator under CO 2 .
- the assay was carried out in triplicate on human keratinocytes in senescence.
- the treatment of keratinocytes with the BB product in the presence and absence of 0.25 mM phloretin was performed for 20 minutes at 37° C.
- the membrane microsomes were separated by differential centrifugation.
- the kinetics of capture of glucose under physiological conditions is higher at the level of microsomes of keratinocytes treated with the BB product compared to control microsomes of keratinocytes. This result is obtained for different incubation periods (30, 60, 90 and 120 seconds).
- the assay was carried out in triplicate on human keratinocytes in senescence.
- the treatment of keratinocytes with the BB product in the presence and absence of 1 mM Diphenhydramin was carried out for 120 minutes at 37° C.
- the membrane microsomes were separated by differential centrifugation.
- the obtained results show that the rate of transport of lipids is markedly lower at keratinocytes in senescence level compared to normal keratinocytes.
- the kinetics of capture of lipids under physiological conditions is comparable for the microsomes of keratinocytes treated with the BB product and the control microsomes of keratinocytes.
- the assay was carried out in triplicate on human keratinocytes in senescence.
- the treatment of keratinocytes in senescence with Nocodazole prior to the separation of microsomes, inhibits the rate of transport of proteins.
- the amount of dissolved oxygen in a solution can be determined with a Clark electrode.
- the oxygen diffusing through a teflon film will be reduced at the level of the platinum cathode polarized at ⁇ 0.8 Volt. Under these conditions, the current passing between this cathode and the silver anode is proportional to the concentration of oxygen in the solution.
- the ionic bridge between both electrodes is created by a saturated solution of KCl.
- the acquisition and the treatment of measurements are carried out with a microcomputer (IBM-PC) in real time.
- IBM-PC microcomputer
- a program allows to continuously visualize the oxygen amount in the tank and the instantaneous derivative as well corresponding to the rate of oxygen consumption calculated in real time.
- the keratinocytes were cultured in incubator with CO 2 , at a rate of 10 6 per run in a culture medium DMEM supplemented with hydrocortisone, EGF and FCS (10%).
- This protocol was carried out by direct application of the product on the cells in the tank of oxygraph.
- the cells (keratinocytes), in a concentration of 10 6 cells/ml, are suspended in a “respiration buffer” (Hanks-Hepes 20 mM glucose), in the tank of oxygraph thermostatised at 30° C. and equipped with a Clark electrode (1 ml of respiration buffer containing under these conditions 480 oxygen atoms).
- the product in contact with the keratinocytes induces a significant increase in the rate of basal respiration in concentrations (1 ⁇ 5 and 1 ⁇ 2).
- the keratinocytes were cultured in incubator under CO 2 , at a rate of 10 6 cells per run, in a culture medium DMEM supplemented with hydrocortisone, EGF and FCS (10%).
- This protocol was carried out by direct application of the product onto the cells in the tank of oxygraph.
- the cells in a concentration of 10 6 cells/ml, are suspended in a “respiratory buffer” (Hanks-Hepes 20 mM glucose), in the tank of oxygraph thermostatized at 30° C. and equipped with a Clark electrode (1 ml respiratory buffer containing under these conditions 480 oxygen atoms).
- the cells are permabilized with digitonin.
- the addition of a respiratory substrate (10 mM pyruvate and 10 mM malate) allows to observe a rate of oxygen consumption (stage 2 according to Chance).
- the addition of different amounts of the product final concentrations: 1/10; 1 ⁇ 5 and 1 ⁇ 2) into the tank of oxygraph allows to reveal a possible stimulation or inhibition of this respiration.
- the measurement is carried out with a device of Luminoscan type using the ATP monitoring reagent (ATP Bioluminescence Assay Kit HS II) by Boehringer Mannheim.
- the amount of ATP present in this aliquot can be determined thanks to the following enzymatic reaction:
- the intensity of the emitted light during this reaction can be measured with a luminometer (Luminoscan) which transcribes it in RLU (relative luminosity units).
- the measured RLU can be converted into mols of ATP with reference to a range of standards of ATP.
- the rate of synthesis of ATP is expressed in mmols/min/10 6 cells.
- the keratinocytes were cultured in incubator under CO 2 , at a rate of 10 6 per run in a culture medium DMEM supplemented with hydrocortisone, EGF and FCS (10%).
- This protocol was carried out by direct application of the product onto the cells in the oxygraph tank.
- the cells (keratinocytes), in a concentration of 10 6 cells/ml, are suspended in a “respiration buffer” (Hanks-Hepes 20 mM glucose), in the tank of oxygraph thermostatized at 30° C.
- the cells are impermeabilized with digitonin.
- the addition of a respiratory substrate (10 mM pyruvate and 10 mM malate) allows to observe a rate of oxygen consumption (stage 2 according to Chance).
- an aliquot is taken in the tank of oxygraph for the ATP assay following the method described hereabove.
- the addition of different amounts of the product into the tank of oxygraph allows to reveal a possible activation or inhibition of the ATP synthesis.
- the amount of ATP, ADP and AMP contained in the cells is measured by High Pressure Liquid Chromatography (HPLC).
- the elution solvent is a potassium phosphate solution; depending on the molarity and the pH thereof, the retention time of nucleotides is more or less long.
- the rate of elution is of 1 ml/min.
- the elution profile is monitored by measuring the absorbance at 254 nm in isocratic.
- a range of standards is carried out between 0.1 and 1 nmol of ATP, of ADP and of AMP measuring the surface of the area under the respective maxima.
- the ATP, ADP and AMP concentrations of a cellular extract (10 6 cells/ml) are assayed by HPLC. They are expressed in nmol/min/mg proteins.
- the energetic charge (E. C.) is calculated following the formula: ([ATP]+1 ⁇ 2[ADP])/([ATP]+[ADP]+[AMP])
- the calculation of the energetic charge is carried out in triplicate on control charges and on treated charges.
- Tested BB product Control 1/10 1 ⁇ 5 1 ⁇ 2 [ATP] 4214 4060 4554 4860 [ADP] 936 1103 1162 936 [AMP] 673 488 719 1178 [ATP/ADP] 4.50 3.68 3.92 5.19 Total 5823 5651 6434 6973 E.C. 0.804 0.816 0.798 0.764
- the product in contact with human keratinocytes in culture induces no modification of the energetic load in the used concentrations of the product.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Edible Seaweed (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
This invention is related to a freeze-dried product of cells of brown algae, the process for obtaining thereof, a cosmetic composition containing thereof, a food complement containing thereof, and the use thereof.
Description
- This invention relates to a freeze-dried product of cells of brown algae, the process for obtaining thereof, a cosmetical composition containing them, a food complement containing them and uses thereof.
- The class of brown algae, also called Fucophycae or Phaeophyceae, belongs to the Division Chromophyta or “colored algae”, frequently called chrysophyta. This Division groups algae the cells of which contain “accessory” carotenoid pigments, such as fucoxanthin, in addition to chlorophyll pigments: chlorophyll a and c.
- The class of brown algae comprises the orders of: Ascoseirales, Chordariales, Cutleriales, Desmarestiales, Dictyosiphonales, Dictyotales, Durvilleales, Ectocarpales, Fucales, Laminariales, Notheiales, Scytosiphonales, Sphacelariales, Sporochnales, Syringodermatales, Tilopteridales.
- All photosynthetic organisms use the pigments to harvest the light energy, usually a form of chlorophyll. The standard chlorophyll is the chlorophyll a, and it is essential for the transfer of the captured light energy to the molecules which will make use of this energy. Most of the chlorophyll organisms have other pigments to absorb more light but the harvested energy must always be transferred to a molecule of chlorophyll a.
- The brown algae make use of several such “accessory” pigments such as the chlorophyll c and the carotenoids. The Phaeophyceae exhibit great amounts of carotenoids in their plastids and these are the brown and yellow pigments which impart them this characteristic brown colour. The most important carotenoid pigment of the brown algae is fucoxanthin, the name of which originates from Fucus. The fucoxanthin absorbs wavelengths of 500 to 580 nm.
- Carotenoid pigments have an aliphatic or alicyclic structure. They are soluble in fats, what furthers their direct integration into certain membranes. Therefore, their solubility in water can only arise when they are bound to other molecules. This is also the reason that their metabolism is most frequently in direct relation to the metabolism of lipids.
- Carotenoids are also called accessory pigments, since they are bound to transfer the energy harvested by chlorophyll a. These pigments are generally known through the caroten which gave its name to this family of pigments.
- The only source of carotenoids, particularly for animals and humans, is their food. The carotenoids have an antioxydant function in the human plasma, especially for the circulating lipids. This function is expressed also at the cell membrane level where they are incorporated.
- The carotenoids have a direct part in the coloration of the skin (yellow-orange) imitating the natural tan.
- Caroten is used as food complement to be taken a few days before and during the exposition to sunlight in order to accelerate the tan. The beta-caroten is the precursor of the vitamin A. The intake of beta-caroten delays the outbreak of solar erythema. Vitamin A increases the amount of melanin produced under the action of a blue light. Further, the vitamin A has an anti-oxydative protective role. The vitamins A and E avoid the oxydative denaturation of the melanin under the action of UV-light.
- In the known food complements, caroten is associated to the vitamin C, the vitamin E or to the flavonoids.
- The drawback to the use of caroten for colouring the skin is that the resulting colour is much more orange-coloured than the natural tan. In addition, it is rapidly degraded to the vitamin A.
- Astaxanthin was shown to be a powerful anti-oxidant. The patent application U.S. Pat. No. 6,433,025 describes the oral use thereof for preventing and delaying sunburns.
- Canthaxanthin, a further carotenoid pigment, was used as food complement for colouring the skin and for protecting thereof against UV rays (GB 1 323 800). Nevertheless, this use of canthaxanthin is prohibited in France because of the danger of blindness while it is currently marketed in the U.S. (Canthorex, DELTA® Laboratories).
- Skin cancer or melanoma will be, in France, in the next years, the most frequent and is already in the U.S. with 800000 cases/year. Most frequently, it is the consequence of an excessive proliferation of skin cells resulting from DNA mutations induced by ultraviolet light (V).
- People become more and more aware of this danger and are ready to protect themselves against the sun. Nevertheless, a tanned skin is still an advantageous and desired feature satisfying present esthetical criteria.
- Therefore, the manufacturers of cosmetics and pharmaceutical preparations are currently investigating active substances for pigmenting the skin and for protecting the skin against the deleterious effects of the UV.
- The Applicant has surprisingly and unexpectedly discovered that a freeze-dried product of cells of brown algae, in particular of gametophytes, enriched in fucoxanthin, allows to achieve this combination of desired effects: it pigments the epidermis in an entirely harmless way by stimulating the melanogenesis, even without UV irradiation, while protecting it by an anti-radical activity and stimulating its regeneration.
- In fact, brown algae have a complex digenetic cycle. For Laminariales (see
FIG. 1 ), the alternation between a diploid sporophyte developed in a macroscopic thalle and the microscopic male gametophytes and female haploids, can be observed. In this case, gametophytes are only a set of cells resulting from different mitoses of the spore. - The gametophyte is transient with time and is only a stage of production of gametes. As it is not developed into a true thalle, it is weakly photosynthetic and contains a maximum amount of protecting pigments: fucoxanthin, compared to the true photosynthesis pigments which are chlorophylls.
- Thus, the Applicant has selected this stage of gametophyte in order to obtain a freeze-dried product of cells of brown algae with an extrement enrichment in fucoxanthin, easily and at low cost, compared to a classical extraction of fucoxanthin, from a biomass available in unlimited amounts and throughout the whole year.
- Thus, the first subject-matter of the present invention is a freeze-dried product of cells of brown algae enriched in fucoxanthin, in particular comprising at least 1% of fucoxanthin. Said cells of brown algae are preferably spores or gametophytes, in a particularly preferred manner, gametophytes.
- The second subject-matter of the present invention is a process for obtaining a freeze-dried product of gametophytes of cells of brown algae comprising the following steps:
- harvesting mature sporophytes
- emission of spores in vitro
- germination of spores in vitro
- harvesting gametophyte cells
- freeze-drying of the obtained gametophyte cells.
- “Mature sporophyte” means a sporophyte comprising spores in special receptacles, for example sores.
- The third subject-matter of the present invention is a cosmetic preparation for topical use comprising a freeze-dried product according to the invention as active ingredient, preferably in an amount ranging from of 0.2 to 5% in weight, more preferably, of 1 to 2% in weight.
- The fourth subject-matter of the present invention is a food complement comprising a freeze-dried product according to the invention as active ingredient.
- The cosmetic preparation according to the invention can be used for pigmenting the skin, for preparing the skin to be exposed to UV rays, for protecting the skin against oxydative stress induced by UV rays and/or for protecting the skin against cellular aging.
- The food complement according to the invention can be used for preparing the skin to be exposed to UV rays.
-
FIG. 1 : reproduction cycle of Laminariales -
FIG. 2 : sections of epidermis treated/untreated stained with HES (hematoxylin/eosine/safran). - Gametophytes cells were obtained for the following species: Laminaria saccharina, Laminaria hyperborea, Alaria esculenta, Undaria pinnatifida.
- Thalli of fertile mature sporophytes were harvested, exhibiting sores (see
FIG. 1 ) at J0 on French coasts in Brittany, between October and February. - They are washed with filtered sea water and cut into pieces of 5 to 10 cm2 which are successively dipped into filtered sea water, bleach 0.2% for 20 to 30 sec, in two tanks with filtered sea water.
- Then, the pieces of thalle were dried on absorbent paper, distributed by 30 on a sheet of absorbent paper and the sheets of absorbent paper were rolled.
- The sheets of rolled absorbent paper containing the pieces of thalli are incubated for 12 h at 15° C. Then they are placed into filtered sea water and afterwards, spores are emitted.
- The spores are incubated in a defined culture medium containing 0.1% of Provasoli solution (see Table 1) in a flask in the presence of light (1800-2000 lux, 24h/24), with slight shaking.
- The temperature is increased by a half degree by day up to 22° C. The medium was renewed fortnightly.
- The spores germinate after 6 to 20 days of culture and the gametophytes are harvested after 10-12 days following the germination (see Table 2).
TABLE 1 Composition of the Provasoli solution for 1 L EDTA 3 g Fe(Cl) 0.08 g Mn(Cl) 0.12 g Zn(Cl) 0.015 g Co(Cl) 0.003 g Ca(SO4) 0.0012 g B(H3BO3) 0.6 g Mo(Na2MoO4) 0.05 g -
TABLE 2 Germination period Obtention of Species in days gametophytes at Laminaria 9 J19-J21 saccharina Laminaria 11-20 J21-J32 hyperborea Alaria esculenta 6-7 J16-J19 Undaria 7 J17-J19 pinnatifida - Inhibition of the gametophyte with a kanamycine-sulfate- and germanium dioxide-free medium for preventing the germination of the plantlet.
- The culture is filtered on a sieve, the cells are rinsed with sea water and freeze-dried in a plate-freeze-drier.
- In order to titer the fucoxanthin by HPLC, an ethanol extraction is performed at a rate of 0.05% of freeze-dried product for 10 ml of 70% ethanol, stirring for 6 h in darkness, then filtration.
- HPLC analysis is performed on a Absorbsphere (Alltech) column with a solvent/gradient:
- A=Ammonium acetate/methanol (20:80)
- B=Acetonitril 90%
- C=Ethyl acetate
- A freeze-dried product of gametophytes of the seaweed Undaria pinnatifida (Laminariaciae) is prepared according to Example 2.
- In order to use this freeze-dried product in a suitable way on skin culture, the freeze-dried product is put back into the culture medium of gametophytes. This mixture is ultrasonicated, then filtered. The result of this filtered product is called <<BB>>.
- 1. —Experimental Protocol
- Keratinocytes of the TR 146 line, spontaneously transformed, amplified, by cell culture in a defined modified MCDB 153 medium were used.
- When cultured on the interface air/liquid in a defined medium, these human keratinocytes form a multilayered epithelium without the cornea layer similar to the human cornea.
- The product to be investigated, in this case the BB product according to Example 3, is applied at a rate of 30 μL onto the surface of eight equivalent cultures using a micro-pipette. These cultures are subsequently incubated at 37° C., 5% of CO2, for 10 minutes, 1 hour, 3 hours and 24 hours, at a rate of two cultures by incubation period.
- Negative (buffered saline solution) and positive (SDS 0.5% and 1%) controls are prepared sterile and applied in the same way on two cultures, respectively.
- These cultures are subsequently incubated at 37° C., 5% of CO2, for 1 hour and 24 hours, at a rate of two cultures by incubation period.
- 2. —Assessment of the Cellular Viability
- The cellular viability is further measured qualitatively after labelling with a vital dye. The MTT system measures the mitochondrial dehydrogenase activity of living cells. The key component is the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide or MTT.
- The salt solutions buffered with MTT, in the absence of phenol red, are yellow coloured. The mitochondrial deshydrogenases of living cells cut the tetrazolium cycle, thus inducing formation of purple formazan crystals, insoluble in aqueous solutions.
- The crystals formed by the viable cells are trapped in the polycarbonate filters which serve as support to epithelial cultures. The cultures turn to a uniform intense blue/purple colour when they are viable, but remain white/yellow in the case of cell mortality.
- The results are compared to negative and positive control substances.
- 0.15 ml of culture medium containing 10% vol/vol of MTT solution are pipetted under each filter/culture support. After an incubation of 30 min at room temperature, the colour of the different cultures is observed.
- Negative control cultures should show an intense blue/purple colour, proof of the viability of mucosa after being in contact for 24 hours.
- Positive control cultures should show a white colour, proof of the cellular mortality as from the 1st hour of contact.
- 3. —Results
TABLE 3 Colour of both cultures PRODUCT 10 min 1 h 3 h 24 h TOXICITY BB blue blue blue white NI Negative control blue blue blue blue NI SDS 0.5% blue white white / I SDS 1% white white / / VI
NI = not irritant
I = irritant
VI = very irritant
4. —Conclusion - Under the applied experimental conditions, the BB product according to Example 3, investigated pure, is not irritant to cells forming the model SKINETHIC® of in vitro reconstructed mucous membrane.
- 1—Experimental Protocol
- Keratinocytes of human origin are plated out on polycarbonate filters of 0.63 cm2 in a defined and supplemented medium (modified MCDB 153). The cells are cultured for 10 days on the air/liquid interface, the culture medium being renewed every two days.
- The thus formed epidermis were used for carrying out the study from the 14th day of culture.
- The test was performed in triplicate after incubation for 24 hours of the product, at a rate of 2 μl by epidermis.
- The control epidermis did not receive any product.
- Epidermis fixed in a 10% formaldehyd solution were embedded into paraffin blocs. Vertical sections of 4 microns were stained with HES (hematoxylin/eosine/safran) and photographs were taken under light microscope.
- If the product is not toxic, the cultures should show basal, spineous, granular cell layers and intact orthokeratosic cornea, and the skin stratification should be regular and normal. The basal layer cells should be polarized vertically. Numerous keratohyalin grains should be visible (in violet) in the stratum granulosum just under the stratum corneum.
- 2—Results
- cf.
FIG. 2 - 3. —Conclusion
- Under the applied experimental conditions, the BB product according to Example 3, investigated pure, has been shown not to be cytotoxic on reconstructed skins SKINETHI C®.
- 1. —Materials and Methods
- The BB product is diluted in ethanol then incorporated into a cosmetic formulation.
- The tested products are:
- a—BB product incorporated in formulation at 0.05%
- b—BB product incorporated in formulation at 0.15%
- c—BB product incorporated in formulation at 0.30%
- They are conserved at 4° C. until use thereof.
- 2. —Biochemical Assessment
- At the end of the incubation, the melanin contained in cell lysates was quantified by a spectrophotometrical method. A range of melanin was carried out in parallel with the assay.
- The results are expressed in jug of melanin per ml of lysate of the cell carpets (average +/−standard deviation SD).
- The statistical significance of the observed differences between the conditions <<treated >> and <<controls >> was assessed by variance analysis to a factor (One Way ANOVA) followed by a test of Bonferroni t-test (*:p<0.05;**:p<0.01).
TABLES 4, 5 and 6 biochemical quantification of the melanic content in reconstructed melanized human epidermis treated/not treated: α- ETOH BB Medium MSH 0.15 without alone 100 nM 0.05 0.15 0.3 re-application WITHOUT UV Melanin 47.3 70.3 56.6 59.9 69.1 70.3 (μg/ml) 67.3 86.9 58.7 60.5 77.2 69.0 75.8 85 56.1 66.1 56 58.5 Average 57.3 80.7 57.1 62.2* 73.1** 69.6* S.D. 14.1 9.1 1.3 3.4 5.7 0.9 % medium 100 141 100 108 128 122 alone % ETOH BB 100 108.8 128 121.9 0.05 +UVA Melanin 57.4 95.6 69.7 63.5 64.7 61.2 (μg/ml) 73.9 84.7 66.3 64.1 66.3 66.3 73.4 107.9 57.3 65.7 Average 68.2 96.1 64.5 64.4 65.5 62.6 S.D. 9.4 11.6 6.4 1.2 1.2 3.3 % medium 100 141 94 94 96 92 alone +UVB Melanin 82.6 99.5 60.7 64.6 40.1 44.8 (μg/ml) 91.4 115.5 65.8 66.1 30.9 65.3 75.3 104.6 67.1 70.5 38.7 64.5 Average 83.1 106.5 64.5 67.1 36.6 58.2 S.D. 8 8.2 3.4 3.1 5 11.6 % medium 100 128 78 81 44 70 alone
3. —Histological Assessment - The epidermis skins ware fixed in formaldehyde from the end of incubation, then embedded in paraffin blocs. Subsequently sections of 4 μm thickness were cut.
- The melanin present in the skin sections was revealed by a specific staining called <<Fontana Masson>>. Said slides by condition were carried out with a magnification ×400. The visualisable melanin on these slides was quantified by image analysis using the Image J program.
- The results are expressed in form of the surface occupied by the melanin (number of pixels the grey scale of which is between 0 and 100; 0=black/255=white) in each slide (average +/−standard deviation, SD).
- The statistical significance of the noted differences between the treated conditions and controls was assessed by a Student's test (*: p<0.05, **: p<0.01; ***: p<0.001).
TABLE 7 Quantification of the melanic content of reconstructed melanized human epidermal skins treated/untreated by image analysis: ETOH BB 0.15 WITH- without OUT Medium α-MSH reappli- UV alone 100 nM 0.05 0.15 0.3 cation Surface 24131 38565 22754 29849 22821 22036 occupied 17119 25757 16628 15245 15368 19500 by the 30306 42233 16392 36248 20144 25949 melanin 13966 55615 12954 7678 19722 16277 (pixels) 9673 51363 22308 6990 21260 11746 19100 43652 7362 10329 18916 19408 13226 44188 4473 10212 20203 42503 20874 44053 17132 22152 25844 19002 26733 22738 17195 25753 17680 30479 18715 34614 9717 15909 17895 14747 Average 19384.3 40277.8 14691.5 18036.5 19985.3* 22164.7* S.D. 6370.9 10308.4 6034.9 10055.1 2911.3 8944.6 % medium 100 208 76 93 103 114 alone % ETOH — — 100 122.8 136 150.9 BB 0.05
3. —Results - The formulation “ETOH BB 0.15” increases significantly the melanin content of reconstructed melanized human epidermal skins, not exposed to UVA or to UVB, without re-application (+22% by biochemical analysis, +51% by image analysis).
- The formulation “ETOH BB 0.3” increases significantly the melanin content in reconstructed in reconstructed melanized human epidermal skins, not exposed to UVA or to UVB (+28% by biochemical analysis, +36% by image analysis).
- 7.1—Assessment of the Rate of Transport of Macromolecules (Glucids, Lipids and Proteins) in a System of Isolated Microsomes. Direct Effect of the BB Product on Isolated Microsomes:
- The microsomes of human keratinocytes form a membrane fraction obtained by high-speed differential centrifugation of a cell homogenate. This preparation of microsomes requires the addition of exogenous cofactors such as NADPH.
- 7.1.1—Transport of Glucids (Glucose)
- The assay was performed in triplicate after the direct treatment of microsomes.
- Charge 1: negative control not receiving any product.
- Charge 2: positive control (0.25 mM phloretin)
- Charges 3-5: treated with the investigated product (3 concentrations)
- Charges 6-8: treated with 0.25 mM phloretin and with the investigated product (3 concentrations)
- The obtained microsomes from human keratinocytes in culture were washed 3 times with a PBS buffer without glucose then pre-incubated in 1 ml of the same buffer for 30 minutes at 37° C. Subsequently, this solution was discarded and the microsomes placed into the glucose-free PBS buffer containing 3-0-Methyl glucose (MG) and [3H] 3-0-MG with stirring in a water-bath at 37° C. The capture of 3-0-MG is stopped by addition of 1 ml of cold PBS containing cytochalasine B. The kinetics of incubation was performed between 30 and 120 seconds. The microsomes were further rinsed 2 times with PBS, then dissolved in NaOH (1M) at 4° C., over night. The radioactivity was determined with a scintillation counter.
- The treatments of microsomes with the BB product alone or in the presence of phloretin were carried out at the same time as the introduction of [3H] 3-0-MG into the incubation medium.
- The protein assay was performed following the BRADFORD method. The increase in absorbance at 595 nm, determined with spectrophotometer, is proportional to the protein concentration.
- Results:
Capture of [3H]3-O-MG (nmol/mg proteins) 30 s 60 s 90 s 120 s Negative control 9 15 19 21 BB 1/10 10 14 20 22 BB ⅕ 9 15 20 22 BB ½ 11 16 21 21 Phloretin (0.25 mM) 4 6 8 8 BB 5 11 17 19 ( 1/10) + Phloretin BB (⅕) + Phloretin 6 12 18 21 BB (½) + Phloretin 7 14 18 22 - The obtained results, after direct treatment of the microsomes of keratinocytes with the BB product in the used concentrations show no inhibition of the transport rate of glucose. The kinetics of glucose capture under physiological conditions is quasi-identical in the control microsomes and the microsomes treated with the BB product in the used 3 concentrations.
- The direct treatment of microsomes with phloretin strongly inhibits the rate of transport of glucose. The treatment of microsomes with the BB product in the 3 concentrations simultaneously with phloretin significantly re-establishes the rate of transport of glucose. The kinetics of glucose capture, under inhibiting conditions, is perfectly re-established with the BB product in the 3 used concentrations.
- 7.1.2—Transport of Lipids
- The assay was performed in triplicate after direct treatment of microsomes.
- Charge 1: negative control not receiving any product.
- Charge 2: positive control (1 mM Diphenhydramin)
- Charge 3-5: treated receiving the investigated product (3 concentrations)
- Charge 6-8: treated with 1 mM Diphenhydramin and with the investigated product (3 concentrations)
- The obtained microsomes from human keratinocytes in culture were rinsed 3 times with 25 mM Tris buffer, then preincubated in 1 ml of the same buffer for 30 minutes at 37° C. This solution was then discarded and the microsomes were placed into the 25 mM Tris buffer containing [3H] Choline with stirring in a water bath at 37° C. The capture of choline was stopped by addition of a lysis buffer containing (50 mM de Tris, 140 mM NaCl, 1.5 mM MgSO4, 0.5% Igepal-Ca-630, 0.2% SDS). The kinetics of incubation was performed between 30 and 120 seconds. Subsequently, the microsomes were rinsed 2 times with PBS then dissolved in NaOH (1M) at 4° C. over night. The radioactivity was determined with a scintillation counter.
- The treatments of microsomes with the BB product alone or in the presence of Diphenhydramin (DPA) were carried out at the same time as the introduction of [3H]Choline into the incubation medium.
- The protein assay was carried out following the BRADFORD method. The increase in absorbance at 595 nm, determined with a spectrophotometer, is proportional to the protein concentration.
- Results
Capture of [3H]choline (pmol/mg proteins) 30 s 60 s 90 s 120 s Negative control 155 201 261 301 BB 1/10 175 212 268 310 BB ⅕ 163 210 277 321 BB ½ 194 240 289 312 DPA (1 mM) 74 105 132 142 BB ( 1/10) + DPA 100 121 153 183 BB (⅕) + DPA 113 131 168 199 BB (½) + DPA 125 140 189 223 - The obtained results, after direct treatment of the microsomes of keratinocytes with the BB product in the used concentrations show no inhibition of the rate of transport of lipids. The kinetics of choline capture under physiological conditions is quasi-identical for the control microsomes and the microsomes treated with the BB product in the 3 used concentrations.
- The obtained results show that the direct treatment of the microsomes with the Diphenhydramin strongly inhibits the rate of transport of lipids. The treatment of microsomes with the BB product in the 3 concentrations at the same time as with the Diphenhydramin restores the rate of transport of lipids. The kinetics of choline capture, under inhibiting conditions is moderately re-established with the BB product in the used 3 concentrations.
- 7.1.3—Transport of Proteins (Albumin)
- The assay was performed in triplicate after the direct treatment of microsomes.
- Charge 1: negative control not receiving any product
- Charge 2: positive control (Nocodazole, 6 mg/ml)
- Charge 3-5: treated receiving the investigated product (3 concentrations)
- Charge 6-8: treated with Nocodazole 6 mg/ml, and with the investigated product (3 concentrations)
- The obtained microsomes from human keratinocytes in culture were rinsed 3 times with a buffer, afterwards pre-incubated in 1 ml of the same buffer for 30 minutes at 3° C. This solution was subsequently discarded and the microsomes were placed into the HBSS buffer containing albumin-FITC with stirring in a water bath at 37° C. The capture of albumin is stopped by addition of a Ringer's solution containing 122.5 mM NaCl; 5.4 mM KCl; 1.2 mM CaCl2; 0.8 mM MgCl2; 0.8 Na2HPO4; 0.2 NaHPO4; 5.5 mM glucose; 10 mM HEPES, pH 7,4. Afterwards, the microsomes were treated with Triton X-100 at (0.1% v/v in 3-(N-morpholino) propanesulfonic acid 20 mM, pH 7.4). The fluorescence was quantified with a spectrophotometer (excitation 480 nm: emission 520 nm). The kinetics of incubation was performed between 30 and 120 seconds.
- The treatment of microsomes with the BB product alone or in the presence of Nocodazole (ND) were carried out at the same time as the introduction of albumin-FITC into the incubation medium.
- The assay of proteins was performed following the BRADFORD method. The increase in absorbance at 595 nm is proportional to the concentration of proteins measured with a spectrophotometer.
- Results:
Capture of albumin-FITC (μg/mg proteins) 30 s 60 s 90 s 120 s Negative control 0.32 0.45 0.55 075 BB 1/10 0.3 0.47 0.59 0.74 BB ⅕ 0.37 0.5 0.62 0.76 BB ½ 0.4 0.55 0.67 0.8 ND (6 mg/ml) 0.11 0.29 0.34 0.43 BB ( 1/10) + ND 0.12 0.3 0.33 0.41 BB (⅕) + ND 0.19 0.33 0.38 0.49 BB (½) + ND 0.23 0.38 0.44 0.57 - The obtained results, after direct treatment of the microsomes of keratinocytes with the BB product in the used concentrations show no inhibition of the rate of transport of proteins. The kinetics of albumin capture under physiogical conditions is quasi-identical for the control microsomes and the microsomes treated with the BB product in the 3 used concentrations.
- The obtained results show that the direct treatment of microsomes with Nocodazole strongly inhibits the rate of transport of lipids. The treatment of microsomes with the BB product in concentrations ⅕ and ½ at the same time as the Nocodazole moderately re-establishes the rate of transport of lipids. No effect was observed in a concentration 1/10.
- 7.2—Assessment of the Rate of Transport of Macromolecules at the Level of Normal Human Keratinocytes
- The applied method was that of explants allowing to obtain, from a biopsy of human skin, keratinocytes in primary cultures. The assays were carried out on keratinocytes between the 2nd and the 4th passage in order to ensure a reproductibility between the different experiences.
- The keratinocytes were divided into multiwell plates (6 wells) at a rate of 105 cells per well in 1 ml of culture medium SKINETHIC supplemented with insulin and hydrocortisone. The cells were incubated in the presence and absence of the investigated product.
- 7.2.1—Transport of Glucides (Glucose)
- The assay was carried out in triplicate on normal human keratinocytes in culture.
- Charge 1: negative control not receiving any product.
- Charge 2: positive control (0.25 mM Phloretin)
- Charge 3: treated receiving the investigated product
- Charges 6-8: treated with 0.25 mM phloretin and the investigated product (3 concentrations)
- The treatment of keratinocytes with the BB product in the presence and absence of 0.25 mM phloretin was carried out for 20 minutes at 37° C. The membrane microsomes were separated by differential centrifugation.
- The same protocol of capture of [3H] 3-0-Methyl-Glucose was adopted for the determination of the rate of transport of glucose. (cf. 6.1.1).
- Results:
Capture of [3H]3-O-MG (nmol/mg of proteins) 30 s 60 s 90 s 120 s Negative control 6 12 15 19 BB 1/10 7 10 16 17 BB ⅕ 8 13 17 18 BB ½ 10 14 18 20 Phloretin (0.25 mM) 6 8 9 10 BB 6 10 15 18 ( 1/10) + Phloretin BB (⅕) + Phloretin 7 13 16 19 BB (½) + Phloretin 8 13 17 18 - The obtained results, after treatment of the normal keratinocytes with the BB product, prior to the separation of microsomes, show no inhibition of the rate of transport of glucose. The kinetics of capture of glucose under physiological conditions is quasi-identical for the control microsomes of keratinocytes and the microsomes of keratinocytes treated with the BB product in the used 3 concentrations.
- The treatment of normal keratinocytes with phloretin, prior to the separation of microsomes, strongly inhibits the rate of transport of glucose. The treatment of normal keratinocytes with the BB product in the 3 concentrations at the same time as with phloretin re-establishes significantly the rate of transport of glucose. The kinetics of capture of glucose, under inhibiting conditions is perfectly restored with the BB product in the used 3 concentrations.
- 7.2.2—Transport of Lipids
- The assay was carried out in triplicate on normal human keratinocytes in culture.
- Charge 1: negative control not receiving any product.
- Charge 2: positive control (1 mM Diphenhydramin)
- Charge 3-5: treated receiving the investigated product (3 concentrations)
- Charge 6-8: treated with 1 mM Diphenhydramin and with the investigated product (3 concentrations)
- The treatment of keratinocytes with the BB product in the presence of 1 mM Diphenhydramin was carried out for 120 minutes at 37° C. The membrane microsomes were separated by differential centrifugation.
- The same protocol of capture of [3H] choline was used for the determination of the speed of transport of choline (cf. 6.1.2)
- Results:
Capture of [3H]choline (pmol/mg proteins) 30 s 60 s 90 s 120 s Negative control 142 173 202 215 BB 1/10 151 163 198 223 BB ⅕ 162 178 207 227 BB ½ 174 191 218 231 DPA (1 mM) 92 115 143 156 BB ( 1/10) + DPA 112 128 159 174 BB (⅕) + DPA 119 132 165 179 BB (½) + DPA 127 139 174 191 - The obtained results, after treatment of the normal keratinocytes with the BB product, prior to the separation of microsomes, show no inhibition of the rate of transport of lipids. The kinetics of capture of choline under physiological conditions is quasi-identical for the control microsomes of keratinocytes and the microsomes of keratinocytes treated with the BB product in the used 3 concentrations.
- The treatment of normal keratinocytes with Diphenhydramin, prior to the separation of microsomes, moderately inhibits the rate of transport of lipids. The treatment of normal keratinocytes with the BB product in 3 concentrations at the same time as the Diphenhydramin restores the rate of transport of lipids. The kinetics of capture of choline, under inhibitory conditions, is moderately restored with the BB product in the used 3 concentrations.
- 7.2.3—Transport of Proteins (Albumin)
- The assay was carried out in triplicate on normal human keratinocytes in culture.
- Charge 1: negative control not receiving any product.
- Charge 2: positive control (Nocodazole, 6 mg/ml)
- Charge 3-5: treated receiving the investigated product (3 concentrations)
- Charge 6-8: treated with Nocodazole, 6 mg/ml, and with the investigated product (3 concentrations)
- The treatment of keratinocytes with the BB product in the presence and absence of Nocodazole, 6 mg/ml, was carried out for 120 minutes at 37° C. The membrane microsomes were separated by differential centrifugation.
- The same protocol of capture of albumin-FITC was used for the determination of the rate of transport of albumin (cf. 3.1.4.2)
- Results:
Capture of albumin-FITC (μg/mg proteins) 30 s 60 s 90 s 120 s Negative control 0.25 0.39 0.45 0.61 BB 1/10 0.24 0.40 0.48 0.63 BB ⅕ 0.28 0.44 0.52 0.67 BB ½ 0.31 0.46 0.54 0.73 S.D. (6 mg/ml) 0.09 0.22 0.26 0.37 BB ( 1/10) + S.D. 0.1 0.24 0.26 0.39 BB (⅕) + S.D. 0.12 0.27 0.30 0.41 BB (½) + S.D. 0.16 0.29 0.36 0.47 - The obtained results, after treatment of normal keratinocytes with the BB product, prior to the separation of microsomes, show no inhibition in the rate of transport of proteins. The kinetics of capture of albumin under physiological conditions is the same for control microsomes of keratinocytes and the microsomes of keratinocytes treated with the BB product in a concentration 1/10. A slight increase in the rate of transport of proteins is noted for concentrations ½ and ⅕.
- The treatment of normal keratinocytes with Nocodazole, prior to the separation of microsomes, inhibits the rate of transport of proteins. The treatment of normal keratinocytes with the BB product in 2 concentrations at the same time as the Nocodazole re-establishes moderately the rate of transport of proteins. No effect was observed in the concentration 1/10.
- 7.3—Assessment of the Rate of Transport of Macromolecules at the Level of Human Keratinocytes in Senescence
- The senescence is a phenomenon of cellular aging, where the cells are arrested in the phase G1 of the cell cycle and never enter the synthesis phase leading to the cell division. Senescent cells are characterized by their slow metabolism at synthesis and transport of macromolecules levels.
- The cells in culture deprived of serum stop their growth, but continue to progress through the cell cycle until they reach the phase G1.
- The applied method allowed to obtain, from a human skin biopsy, primary cultures of keratinocytes. The assays were performed on keratinocytes, between the 8th and the 10th passage, in order to ensure the presence of senescent cells at control cells level.
- The keratinocytes were seeded in multiwell plates (6 wells) at a rate of 105 cells per well in 3 ml of culture medium SKINETHIC supplemented with EGF, hydrocortisone, insulin and gentamicyn. Afterwards they are maintained for 5 days in incubator under CO2.
- 7.3.1—Transport of Glucids (Glucose)
- The assay was carried out in triplicate on human keratinocytes in senescence.
- Charge 1: negative control not receiving any product.
- Charge 2: positive control (0.25 mM Phloretin)
- Charge 3: treated receiving the investigated product
- Charges 6-8: treated with 0.25 mM phloretin and with the investigated product (3 concentrations)
- The treatment of keratinocytes with the BB product in the presence and absence of 0.25 mM phloretin was performed for 20 minutes at 37° C. The membrane microsomes were separated by differential centrifugation.
- The same protocol of capture of [3H] 3-0-Methyl-Glucose was applied to the determination of the rate of transport of glucose (cf. 6.1.1).
- Results:
Capture of [3H]3-O-MG (nmol/mg of proteins) 30 s 60 s 90 s 120 s Negative control 3 5 10 11 BB 1/10 4 8 12 12 BB ⅕ 6 8 13 13 BB ½ 7 10 14 15 Phloretin (0.25 mM) 1 3 5 7 BB 3 5 7 8 ( 1/10) + Phloretin BB (⅕) + Phloretin 5 8 9 11 BB (½) + Phloretin 6 10 12 13 - The obtained results show that the rate of transport of glucose is markedly low at the keratinocytes in senescence level compared to normal keratinocytes.
- The treatment of keratinocytes in senescence with the BB product, prior to the separation of microsomes, shows an increase in the rate of transport of glucose compared to the untreated control cells. The kinetics of capture of glucose under physiological conditions is higher at the level of microsomes of keratinocytes treated with the BB product compared to control microsomes of keratinocytes. This result is obtained for different incubation periods (30, 60, 90 and 120 seconds).
- The treatment of keratinocytes in senescence with phloretin, prior to the separation of microsomes, strongly inhibits the rate of transport of glucose. The treatment of normal keratinocytes with the BB product in 2 concentrations (⅕ and ½) at the same time as with phloretin restores significantly the rate of transport of glucose. A slight effect was observed in the concentration 1/10.
- 7.3.2—Transport of Lipids
- The assay was carried out in triplicate on human keratinocytes in senescence.
- Charge 1: negative control not receiving any product.
- Charge 2: positive control (1 mM Diphenhydramin)
- Charge 3-5: treated receiving the investigated product (3 concentrations)
- Charge 6-8: treated with 1 mM Diphenhydramin and with the investigated product (3 concentrations)
- The treatment of keratinocytes with the BB product in the presence and absence of 1 mM Diphenhydramin was carried out for 120 minutes at 37° C. The membrane microsomes were separated by differential centrifugation.
- The same protocol of capture of [3H] Choline was applied to the determination of the rate of transport of choline (cf. 6.1.2)
- Results:
Capture of [3H]choline (pmol/mg of proteins) 30 s 60 s 90 s 120 s Negative control 114 132 164 181 BB 1/10 110 135 166 173 BB ⅕ 113 143 188 194 BB ½ 121 153 187 201 DPA (1 mM) 55 79 106 119 BB ( 1/10) + DPA 52 69 110 125 BB (⅕) + DPA 67 87 132 141 BB (½) + DPA 77 104 137 148 - The obtained results show that the rate of transport of lipids is markedly lower at keratinocytes in senescence level compared to normal keratinocytes.
- The treatment of keratinocytes in senescence with the BB product, prior to the separation of microsomes, shows no inhibition of the rate of transport of lipids compared to untreated control cells. The kinetics of capture of lipids under physiological conditions is comparable for the microsomes of keratinocytes treated with the BB product and the control microsomes of keratinocytes.
- The treatment of keratinocytes in senescence with Diphenhydramin, prior to the separation of microsomes, strongly inhibits the rate of transport of lipids. The treatment of keratinocytes in senescence with the BB product in 2 concentrations (⅕ and ½) at the same time as with Diphenhydramin re-establishes significantly the rate of transport of lipids. No effect was observed in the concentration 1/10.
- 7.3.3—Transport of Proteins (Albumin)
- The assay was carried out in triplicate on human keratinocytes in senescence.
- Charge 1: negative control not receiving any product.
- Charge 2: positive control (Nocodazole, 6 mg/ml)
- Charge 3-5: treated receiving the investigated product (3 concentrations)
- Charge 6-8: treated with Nocodazole, 6 mg/ml, and the investigated product (3 concentrations)
- The treatment of keratinocytes with the BB product in the presence and absence of Nocodazole, 6 mg/ml, was carried out for 120 minutes at 37° C. The membrane microsomes were separated by differential centrifugation.
- The same protocol of capture of albumin-FITC was applied to determine the rate of transport of albumin (cf. 6.1.3)
- Results:
Capture of albumin-FITC (μg/mg of proteins) 30 s 60 s 90 s 120 s Negative 0.17 0.29 0.35 0.49 control BB 1/10 0.18 0.34 0.39 0.52 BB ⅕ 0.18 0.36 0.41 0.54 BB ½ 0.2 0.37 0.43 0.55 ND (6 mg/ml) 0.06 0.11 0.19 0.3 BB ( 1/10) + ND 0.05 0.12 0.22 0.33 BB (⅕) + ND 0.09 0.14 0.27 0.38 BB (½) + ND 0.1 0.19 0.3 0.43 - The obtained results demonstrate that the rate of transport of proteins is markedly lower at the keratinocytes in senescence level compared to normal keratinocytes. The treatment of keratinocytes in senescence with the BB product, prior to the separation of microsomes, shows no inhibition of the rate of transport of proteins compared to the untreated control cells. The kinetics of capture of albumin under physiological conditions is comparable for the microsomes of keratinocytes treated with the BB product and the control microsomes of keratinocytes.
- The treatment of keratinocytes in senescence with Nocodazole, prior to the separation of microsomes, inhibits the rate of transport of proteins. The treatment of keratinocytes in senescence with the BB product in 2 concentrations (⅕ and ½), at the same time as with Nocodazole, restores significantly the rate of transport of proteins. A slight effect is observed with the concentration 1/10.
- 8.1—Study of the Effect of the Product on Mitochondial and Cellular Respiration
- The amount of dissolved oxygen in a solution can be determined with a Clark electrode. The oxygen diffusing through a teflon film will be reduced at the level of the platinum cathode polarized at −0.8 Volt. Under these conditions, the current passing between this cathode and the silver anode is proportional to the concentration of oxygen in the solution. The ionic bridge between both electrodes is created by a saturated solution of KCl.
- The acquisition and the treatment of measurements are carried out with a microcomputer (IBM-PC) in real time. A program allows to continuously visualize the oxygen amount in the tank and the instantaneous derivative as well corresponding to the rate of oxygen consumption calculated in real time.
- Five concentrations were tested and the determinations were carried out in triplicate. This study is carried out depending on two different conditions:
- 8.1.1—Effect of the Product on Cellular Respiration: Measurement of Basal Respiration
- Effect on the rate of basal respiration on non permeabilized cells in the presence of glucose.
- The keratinocytes were cultured in incubator with CO2, at a rate of 106 per run in a culture medium DMEM supplemented with hydrocortisone, EGF and FCS (10%).
- This protocol was carried out by direct application of the product on the cells in the tank of oxygraph.
- The cells (keratinocytes), in a concentration of 106 cells/ml, are suspended in a “respiration buffer” (Hanks-Hepes 20 mM glucose), in the tank of oxygraph thermostatised at 30° C. and equipped with a Clark electrode (1 ml of respiration buffer containing under these conditions 480 oxygen atoms).
- Under these conditions, a rate of oxygen consumption (basal respiration of cells) can be measured. The addition of different amounts of the product (final concentrations: 1/10; ⅕ and ½) in the tank of oxygraph allows to reveal a possible stimulation or inhibition of this breathing.
- All determinations are resumed in the following Table hereafter.
Tested product (BB) Control 1/10 ⅕ ½ Rate of 3.64 ± 0.37 3.72 ± 0.31 4.26 ± 0.25 4.75 ± 0.50 respiration (n atom O/min/ 106 cells) n = 3 % of basal 100 ± 6 102 ± 4 117 ± 3 130 ± 5 respiration n = 3 - Under the applied experimental conditions and considering the obtained results, the product in contact with the keratinocytes induces a significant increase in the rate of basal respiration in concentrations (⅕ and ½).
- 8.1.2. —Effect of the Product on Mitochondrial Respiration:
- Effect on the rate of respiration of permeabilized cells in the presence of the respiration substrate, pyruvate-malate, in order to assess the mitochondrial respiration.
- The keratinocytes were cultured in incubator under CO2, at a rate of 106 cells per run, in a culture medium DMEM supplemented with hydrocortisone, EGF and FCS (10%).
- This protocol was carried out by direct application of the product onto the cells in the tank of oxygraph.
- The cells (keratinocytes), in a concentration of 106 cells/ml, are suspended in a “respiratory buffer” (Hanks-Hepes 20 mM glucose), in the tank of oxygraph thermostatized at 30° C. and equipped with a Clark electrode (1 ml respiratory buffer containing under these conditions 480 oxygen atoms). The cells are permabilized with digitonin. The addition of a respiratory substrate (10 mM pyruvate and 10 mM malate) allows to observe a rate of oxygen consumption (stage 2 according to Chance). The addition of different amounts of the product (final concentrations: 1/10; ⅕ and ½) into the tank of oxygraph allows to reveal a possible stimulation or inhibition of this respiration.
- All determinations are resumed in the Table hereafter.
Tested product (BB) Control 1/10 ⅕ ½ Rate of 2.67 ± 0.21 2.83 ± 0.15 3.25 ± 0.11 3.52 ± 0.09 respiration (n atom O/min/ 106 cells) n = 3 % of basal 100 ± 2 106 ± 4 122 ± 3 132 ± 5 respiration n = 3 - Under the applied experimental conditions and considering the obtained results, the product in contact with human keratinocytes in culture induces a significant increase in the rate of mitochondrial respiration in concentrations (⅕ and ½).
- 8.2—Study of the Effect of the Product on Mitochondrial ATP Synthesis
-
- The intensity of the emitted light during this reaction can be measured with a luminometer (Luminoscan) which transcribes it in RLU (relative luminosity units). The measured RLU can be converted into mols of ATP with reference to a range of standards of ATP.
- The rate of synthesis of ATP is expressed in mmols/min/106 cells.
- Five concentrations were tested and the determinations were carried out in triplicate.
- The keratinocytes were cultured in incubator under CO2, at a rate of 106 per run in a culture medium DMEM supplemented with hydrocortisone, EGF and FCS (10%).
- This protocol was carried out by direct application of the product onto the cells in the oxygraph tank.
- The cells (keratinocytes), in a concentration of 106 cells/ml, are suspended in a “respiration buffer” (Hanks-Hepes 20 mM glucose), in the tank of oxygraph thermostatized at 30° C. The cells are impermeabilized with digitonin. The addition of a respiratory substrate (10 mM pyruvate and 10 mM malate) allows to observe a rate of oxygen consumption (stage 2 according to Chance). After addition of different amounts of the product (concentrations: 1/10; ⅕ and ½) into the tank of oxygraph and at regular intervals, an aliquot is taken in the tank of oxygraph for the ATP assay following the method described hereabove. The addition of different amounts of the product into the tank of oxygraph, allows to reveal a possible activation or inhibition of the ATP synthesis.
- All determinations are resumed in the following Table herebelow.
Tested product (BB) Control 1/10 ⅕ ½ Rate of ATP 5.78 ± 0.25 6.16 ± 0.34 6.96 ± 0.29 7.24 ± 0.54 synthesis (nmol/min/ 106 cells) n = 3 % of ATP 100 ± 3 107 ± 5 120 ± 8 125 ± 6 synthesis n = 3 - Under the applied experimental conditions and considering the obtained results, the product in contact with human keratinocytes in culture induces a significant increase in the rate of mitochondrial ATP synthesis in concentrations (⅕ and ½).
- 8.3—Study of the Effect of the Product on Energetic Metabolism
- Assessment of the effect of the product at the energetic metabolism level by measurement of the concentrations of adenylic nucleotides. The study was carried out on primary cultures of human keratinocytes treated for 5 days prior to the study.
- The amount of ATP, ADP and AMP contained in the cells is measured by High Pressure Liquid Chromatography (HPLC).
- On a Beckman device, a column (10×0.46 cm) with a support Spherisorb NH2 with a granulometry of 5 μm was used. The elution solvent is a potassium phosphate solution; depending on the molarity and the pH thereof, the retention time of nucleotides is more or less long. The rate of elution is of 1 ml/min. The elution profile is monitored by measuring the absorbance at 254 nm in isocratic.
- A range of standards is carried out between 0.1 and 1 nmol of ATP, of ADP and of AMP measuring the surface of the area under the respective maxima.
- Five concentrations were tested and the determinations were carried out in triplicate.
- The ATP, ADP and AMP concentrations of a cellular extract (106 cells/ml) are assayed by HPLC. They are expressed in nmol/min/mg proteins. The energetic charge (E. C.) is calculated following the formula:
([ATP]+½[ADP])/([ATP]+[ADP]+[AMP]) - The calculation of the energetic charge is carried out in triplicate on control charges and on treated charges.
- All determinations are resumed in the Table hereafter.
- The ATP, ADP and AMP concentrations are expressed in nmol/mg proteins (n=3).
Tested BB product Control 1/10 ⅕ ½ [ATP] 4214 4060 4554 4860 [ADP] 936 1103 1162 936 [AMP] 673 488 719 1178 [ATP/ADP] 4.50 3.68 3.92 5.19 Total 5823 5651 6434 6973 E.C. 0.804 0.816 0.798 0.764 - Under the applied experimental conditions and considering the obtained results, the product in contact with human keratinocytes in culture induces no modification of the energetic load in the used concentrations of the product.
Claims (17)
1. A freeze-dried product of cells of brown algae enriched with fucoxanthin.
2. A freeze-dried product according to claim 1 , wherein said cells of brown algae are gametophytes cells.
3. A freeze-dried product according to claim 1 , including at least 1% of fucoxanthin.
4. A process for obtaining a freeze-dried product according to claim 2 , including the following steps:
harvesting mature sporophytes
emission of spores in vitro
germination of spores in vitro
harvesting gametophytes cells
freeze-drying of the obtained gametophytes cells.
5. A cosmetic preparation for topical use including a freeze-dried product according to claim 1 , as active ingredient.
6. A cosmetic preparation according to claim 5 , said freeze-dried product being in the range of 0.2 a 5% in weight.
7. A food complement including a freeze-dried product according to claim 1 , as active ingredient.
8. A use of a cosmetic preparation according to claim 5 for pigmenting the skin.
9. A use of a cosmetic preparation according to claim 5 for preparing the skin to be exposed to UV rays.
10. A use of a cosmetic preparation according to claim 5 for protecting the skin against the oxydative stress induced by UV rays.
11. A use of a cosmetic preparation according to claim 5 for protecting the skin against cellular aging.
12. A use of a food complement according to claim 7 for preparing the skin to be exposed to UV rays.
13. A method for pigmenting the skin which comprises topically applying a cosmetic preparation according to claim 5 .
14. A method for preparing the skin to be exposed to UV rays which comprises topically applying a cosmetic preparation according to claim 5 .
15. A method for protecting the skin against the oxydative stress induced by U rays which comprises topically applying a cosmetic preparation according to claim 5 .
16. A method for protecting the skin against cellular aging which comprises topically applying a cosmetic preparation according to claim 5 .
17. A method for preparing the skin to be exposed to UV rays which comprises administering a food complement according to claim 7.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0500389A FR2880803B1 (en) | 2005-01-14 | 2005-01-14 | LYOPHILIZATION OF BROWN ALGAE CELLS, PROCESS FOR OBTAINING AND USES |
| FR0500389 | 2005-01-14 | ||
| PCT/FR2005/003125 WO2006075059A1 (en) | 2005-01-14 | 2005-12-14 | Brown algae cell lyophilisate, method for the obtention thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/FR2005/003125 A-371-Of-International WO2006075059A1 (en) | 2005-01-14 | 2005-12-14 | Brown algae cell lyophilisate, method for the obtention thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/092,180 Division US20140087448A1 (en) | 2005-01-14 | 2013-11-27 | Process for obtaining a brown algae lyophilisate, and cosmetic preparations thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20080089851A1 true US20080089851A1 (en) | 2008-04-17 |
Family
ID=34953243
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/813,861 Abandoned US20080089851A1 (en) | 2005-01-14 | 2005-12-14 | Brown Algae Cell Lyophilisate, Method For The Obtention Thereof |
| US14/092,180 Abandoned US20140087448A1 (en) | 2005-01-14 | 2013-11-27 | Process for obtaining a brown algae lyophilisate, and cosmetic preparations thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/092,180 Abandoned US20140087448A1 (en) | 2005-01-14 | 2013-11-27 | Process for obtaining a brown algae lyophilisate, and cosmetic preparations thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20080089851A1 (en) |
| EP (1) | EP1841508B1 (en) |
| JP (1) | JP4979592B2 (en) |
| KR (1) | KR101087834B1 (en) |
| AU (1) | AU2005324815B2 (en) |
| BR (1) | BRPI0519812B1 (en) |
| CA (1) | CA2594725C (en) |
| FR (1) | FR2880803B1 (en) |
| UA (1) | UA94394C2 (en) |
| WO (1) | WO2006075059A1 (en) |
| ZA (1) | ZA200706646B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100152286A1 (en) * | 2008-11-17 | 2010-06-17 | Beijing Gingko Group Biological Technology Co., Ltd. | Method for Producing Fucoxanthin |
| WO2012093388A3 (en) * | 2011-01-03 | 2012-11-01 | Nidaria Technology Ltd. | Biologic sunscreen compositions based on non-viable whole cell algae |
| CN107427452A (en) * | 2015-02-24 | 2017-12-01 | 化工产品开发公司Seppic | The purposes of extract and the extract as cosmetics anti-aging actives is obtained by brown alga gametophyte |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008291004A (en) * | 2007-04-26 | 2008-12-04 | Oriza Yuka Kk | Composition for beautiful skin |
| FR2918564B1 (en) * | 2007-07-13 | 2017-09-29 | Pacific Creation | USE OF LIPOPHILIC EXTRACT OF ODONTELLA AURITA FOR SKIN RESTRUCTURING, COMPOSITIONS USED AND COSMETIC PROCESS USING SUCH EXTRACT |
| ES2441469B2 (en) * | 2013-04-12 | 2014-07-04 | Universidade De Santiago De Compostela | Antioxidant extract from brown macroalgae and obtaining procedure |
| JP6675878B2 (en) * | 2016-02-06 | 2020-04-08 | 富士産業株式会社 | Topical composition for hair growth and hair growth |
| JPWO2024176965A1 (en) * | 2023-02-22 | 2024-08-29 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2697409A1 (en) * | 1992-11-03 | 1994-05-06 | Nature Algues | Removal of iodine@ from seaweed extracts, useful in mfr. of foodstuffs, dietetic prods., cosmetics etc. - by alcohol extraction of spray- or freeze-dried extract |
| US5508033A (en) * | 1989-12-06 | 1996-04-16 | Societe D'engrais Composes Mineraux Et Amendments | Utilization of algae extract for the preparation of pharmaceutical, cosmetic, food or agricultural compositions |
| US6433025B1 (en) * | 2000-04-13 | 2002-08-13 | Cyanotech Corporation | Method for retarding and preventing sunburn by UV light |
| US20030017185A1 (en) * | 1998-04-13 | 2003-01-23 | Kao Corporation | Cosmetic composition |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH500711A (en) * | 1966-02-14 | 1970-12-31 | Bouclet Andre | Method for the preparation of an algae powder of particle size 0.1-5 mu for use as pharmaceutical, cosmetic or food preparation, in which the algae cells are bu |
| FR2489689B1 (en) * | 1980-09-11 | 1986-03-07 | Heitz Jean | CLAY COMPOSITION FOR AESTHETIC OR THERAPEUTIC TREATMENT BY HUMAN BODY BATHS |
| JP3501836B2 (en) * | 1994-02-15 | 2004-03-02 | 財団法人産業創造研究所 | Antioxidant and antioxidant method using fucoxanthin |
| JPH11266726A (en) * | 1998-03-18 | 1999-10-05 | Kaiso Shigen Kenkyusho:Kk | Freeze preservation and defrosting of seaweed gametophyte |
| JP3770588B2 (en) * | 2001-03-06 | 2006-04-26 | 株式会社コーセー | Topical skin preparation |
| FR2838341B1 (en) * | 2002-04-10 | 2007-07-27 | Gelyma | MARINE ALGAE EXTRACT OF THE GENUS CYSTOSEIRA AND USE IN CARE PRODUCTS |
| JP4297654B2 (en) * | 2002-07-08 | 2009-07-15 | 株式会社トロピカルテクノセンター | Method for obtaining fucoxanthin and / or fucosterol |
| JP4109511B2 (en) * | 2002-08-21 | 2008-07-02 | 株式会社小倉屋山本 | Method for purifying fucoxanthin |
| FR2844449B1 (en) * | 2002-09-12 | 2008-03-14 | Codif Internat Sa | USE OF AN EXTRACT FROM A BROWN ALGAE OF THE GENUS HALOPTERIS IN A COSMETIC OR PHARMACEUTICAL COMPOSITION |
-
2005
- 2005-01-14 FR FR0500389A patent/FR2880803B1/en not_active Expired - Lifetime
- 2005-12-14 KR KR1020077018019A patent/KR101087834B1/en not_active Expired - Fee Related
- 2005-12-14 US US11/813,861 patent/US20080089851A1/en not_active Abandoned
- 2005-12-14 JP JP2007550810A patent/JP4979592B2/en not_active Expired - Fee Related
- 2005-12-14 WO PCT/FR2005/003125 patent/WO2006075059A1/en not_active Ceased
- 2005-12-14 EP EP05825973.0A patent/EP1841508B1/en not_active Expired - Lifetime
- 2005-12-14 CA CA2594725A patent/CA2594725C/en not_active Expired - Fee Related
- 2005-12-14 AU AU2005324815A patent/AU2005324815B2/en not_active Ceased
- 2005-12-14 BR BRPI0519812A patent/BRPI0519812B1/en not_active IP Right Cessation
- 2005-12-14 UA UAA200709244A patent/UA94394C2/en unknown
-
2007
- 2007-08-10 ZA ZA200706646A patent/ZA200706646B/en unknown
-
2013
- 2013-11-27 US US14/092,180 patent/US20140087448A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5508033A (en) * | 1989-12-06 | 1996-04-16 | Societe D'engrais Composes Mineraux Et Amendments | Utilization of algae extract for the preparation of pharmaceutical, cosmetic, food or agricultural compositions |
| FR2697409A1 (en) * | 1992-11-03 | 1994-05-06 | Nature Algues | Removal of iodine@ from seaweed extracts, useful in mfr. of foodstuffs, dietetic prods., cosmetics etc. - by alcohol extraction of spray- or freeze-dried extract |
| US20030017185A1 (en) * | 1998-04-13 | 2003-01-23 | Kao Corporation | Cosmetic composition |
| US6433025B1 (en) * | 2000-04-13 | 2002-08-13 | Cyanotech Corporation | Method for retarding and preventing sunburn by UV light |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100152286A1 (en) * | 2008-11-17 | 2010-06-17 | Beijing Gingko Group Biological Technology Co., Ltd. | Method for Producing Fucoxanthin |
| US8871217B2 (en) * | 2008-11-17 | 2014-10-28 | Beijing Gingko Group Biological Technology Co., Ltd. | Method for producing fucoxanthin |
| WO2012093388A3 (en) * | 2011-01-03 | 2012-11-01 | Nidaria Technology Ltd. | Biologic sunscreen compositions based on non-viable whole cell algae |
| CN107427452A (en) * | 2015-02-24 | 2017-12-01 | 化工产品开发公司Seppic | The purposes of extract and the extract as cosmetics anti-aging actives is obtained by brown alga gametophyte |
| US10206869B2 (en) | 2015-02-24 | 2019-02-19 | Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic | Obtaining an extract from brown algae gametophytes, and use of said extract as a cosmetic anti-aging active principle |
| CN107427452B (en) * | 2015-02-24 | 2021-04-09 | 化工产品开发公司Seppic | Extract obtained from brown algae gametophyte and use of said extract as antiaging active ingredient in cosmetics |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1841508A1 (en) | 2007-10-10 |
| BRPI0519812B1 (en) | 2017-05-16 |
| FR2880803A1 (en) | 2006-07-21 |
| EP1841508B1 (en) | 2017-02-22 |
| ZA200706646B (en) | 2008-09-25 |
| AU2005324815A1 (en) | 2006-07-20 |
| JP4979592B2 (en) | 2012-07-18 |
| BRPI0519812A2 (en) | 2009-03-17 |
| KR101087834B1 (en) | 2011-11-30 |
| US20140087448A1 (en) | 2014-03-27 |
| KR20070096001A (en) | 2007-10-01 |
| FR2880803B1 (en) | 2007-03-09 |
| UA94394C2 (en) | 2011-05-10 |
| CA2594725C (en) | 2012-04-24 |
| AU2005324815B2 (en) | 2011-08-25 |
| WO2006075059A1 (en) | 2006-07-20 |
| JP2008526929A (en) | 2008-07-24 |
| CA2594725A1 (en) | 2006-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20140087448A1 (en) | Process for obtaining a brown algae lyophilisate, and cosmetic preparations thereof | |
| CN111557875B (en) | Skin care composition for resisting light pollution and light injury and preparation method and application thereof | |
| US7604806B2 (en) | Use of a lyophilisate of dedifferentiated plant cells for skin depigmentation and/or lightening | |
| CN108430485B (en) | Anti-pollution complex comprising oily and water extracts of Calendula officinalis and water extract of Lilium candidum bulb and use thereof | |
| EP3280497B1 (en) | Hydroalcoholic extract ofschinus molle, cosmetic compositions comprising the same and cosmetic uses thereof | |
| CA2908535A1 (en) | Cosmetic and pharmaceutical applications of lactobacillus pentosus | |
| US10206867B2 (en) | Alcoholic extract of aerial parts of Solidago virgaurea subsp. alpestris, method of production thereof, and cosmetic or dermatological composition containing it | |
| KR20160011732A (en) | Extraction method extracting Sea Buckthorn leaves extracts by low-temperature ripening extracts and anti-oxidant activation and cosmetic compositions with superior whitening effect by the extraction method | |
| EP2958547B1 (en) | Cosmetic use of queuine | |
| EP4281095A1 (en) | Extract of top growth of holy basil, and cosmetic or dermatological compositions containing same | |
| WO2009056773A2 (en) | Cosmetic use of an extract of cicer arietinum, active ingredient, method for obtaining same and compositions | |
| KR20160137950A (en) | Cosmetic use of an extract of gymnema sylvestre | |
| IT202100019727A1 (en) | COMPOSITION TO PREVENT AND TREAT ALTERATIONS AND DISEASES OF THE NAILS | |
| US20140377390A1 (en) | Cosmetic Compositions Comprising Plant Extracts for Combating Skin Aging | |
| FR3164122A1 (en) | Active complex to increase cellular mitochondrial respiration of keratinocytes underlying the stratum corneum of the epidermis | |
| WO2014109426A1 (en) | Cosmetic composition comprising bacteriochlorophyll-containing microbial cell piece as active ingredient | |
| KR20100109393A (en) | Method of cosmetic care stimulating mitochondrial aconitase | |
| EP3002043A1 (en) | A method for preparing an olive extract with a melanin content greater than 5% |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: BIOTECH MARINE, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MEKIDECHE, NICOLE;REEL/FRAME:019552/0395 Effective date: 20060203 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |